BEAM peer analysis
Beam Therapeutics (BEAM) against its competitors: price, today's move, 1-year return and market value side by side.
BEAM and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALLO Allogene Therapeutics | $1.18 | -5.60% | -2.48% | $407.68M |
| CLLS Cellectis | $1.08 | -7.69% | -68.97% | $108.79M |
| CRBU Caribou Biosciences | $0.42 | -4.90% | -81.76% | – |
| CRSP CRISPR Therapeutics | $49.57 | -3.60% | -18.87% | $4.97B |
| DTIL Precision BioSciences | $7.06 | -5.11% | -18.00% | $194.87M |
| EDIT Editas Medicine | $2.57 | -3.75% | -14.62% | $410.06M |
| FATE Fate Therapeutics | $2.08 | -4.15% | 61.24% | $249.23M |
| NTLA Intellia | $11.67 | -6.42% | -4.85% | $1.75B |
| BEAM Beam Therapeutics | $25.86 | -5.03% | 8.66% | $2.81B |
- BEAM's peers: ALLO (Allogene Therapeutics), CLLS (Cellectis), CRBU (Caribou Biosciences), CRSP (CRISPR Therapeutics), DTIL (Precision BioSciences), EDIT (Editas Medicine), FATE (Fate Therapeutics), NTLA (Intellia).
Updated 2026-11-03 00:02 UTC